^
Association details:
| Biomarker: | UGT1A1∗1 |
|---|---|
| Cancer: | Colorectal Cancer |
| Drug: | Avastin (bevacizumab) (VEGF-A inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Determination of the UGT1A1 polymorphism as guidance for irinotecan dose escalation in metastatic colorectal cancer treated with first-line bevacizumab and FOLFIRI (PURE FIST)
Published date:
08/20/2020
Excerpt:
The control group received conventional biweekly FOLFIRI plus bevacizumab without UGT1A1 genotyping, whereas the study group received the same regimen with irinotecan dose escalation based on UGT1A1 genotyping….The median PFS was 14.0 and 10.0 months in the study and control group, respectively...our study provides evidence that higher-than-recommended doses of irinotecan might be safely implemented in the FOLFIRI regimen plus bevacizumab for mCRC patients with UGT1A1∗1/∗1 and UGT1A1∗1/∗28 genotypes...
Secondary therapy:
FOLFIRI + irinotecan
DOI:
https://doi.org/10.1016/j.ejca.2020.05.031
Trial ID:
